Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBITDA (2016 - 2025)

Historic EBITDA for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.7 million.

  • Theravance Biopharma's EBITDA rose 12896.4% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.7 million, marking a year-over-year increase of 17592.31%. This contributed to the annual value of -$46.9 million for FY2024, which is 1621.49% up from last year.
  • Theravance Biopharma's EBITDA amounted to $3.7 million in Q3 2025, which was up 12896.4% from $54.8 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year EBITDA high stood at $916.6 million for Q3 2022, and its period low was -$79.7 million during Q1 2021.
  • Over the past 5 years, Theravance Biopharma's median EBITDA value was -$13.6 million (recorded in 2025), while the average stood at $30.7 million.
  • As far as peak fluctuations go, Theravance Biopharma's EBITDA soared by 269632.6% in 2022, and later plummeted by 10096.98% in 2023.
  • Quarter analysis of 5 years shows Theravance Biopharma's EBITDA stood at -$56.2 million in 2021, then skyrocketed by 68.96% to -$17.4 million in 2022, then surged by 64.2% to -$6.2 million in 2023, then plummeted by 47.44% to -$9.2 million in 2024, then soared by 139.75% to $3.7 million in 2025.
  • Its EBITDA stands at $3.7 million for Q3 2025, versus $54.8 million for Q2 2025 and -$13.6 million for Q1 2025.